NCT06564428 A Cohort Study of Hereditary Ovarian Cancer Risk Prediction Models and Pathogenesis Exploration
| NCT ID | NCT06564428 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University Third Hospital |
| Condition | Ovarian Neoplasms |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2024-01-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2024-01-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this project is to establish a bidirectional multicenter cohort of hereditary ovarian cancer and to describe the clinicopathologic features of hereditary ovarian cancer patients in our country. The risk prediction model of ovarian cancer for Chinese was established by following-up analysis of clinical and pathological information, genetic test results and detailed family history, to predict the risk of cancer in first-degree relatives of carriers of pathogenic/suspected pathogenic mutations, and to guide the intervention management of high-risk population of cancer. The study will identify novel tumor-causing mutations/predisposing genes by gene sequencing in a special family with hereditary tumor.
Eligibility Criteria
Inclusion Criteria: * Epithelial ovarian cancer * ≥18 years * The pathological diagnosis was clear * The genetic test showed germ line pathogenic/suspected pathogenic mutations (for mutation interpretation, refer to the American ACMG Classification Standards and Guidelines for Genetic Variation) Exclusion Criteria: * Non-epithelial ovarian cancer was confirmed by pathology * No genetic test has been performed
Contact & Investigator
Hongyan Guo, Doctor
PRINCIPAL INVESTIGATOR
Peking University Third Hospital
Frequently Asked Questions
Who can join the NCT06564428 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Ovarian Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06564428 currently recruiting?
Yes, NCT06564428 is actively recruiting participants. Contact the research team at yuanli@bimu.edu.cn for enrollment information.
Where is the NCT06564428 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06564428 clinical trial?
NCT06564428 is sponsored by Peking University Third Hospital. The principal investigator is Hongyan Guo, Doctor at Peking University Third Hospital. The trial plans to enroll 1,000 participants.